Updates are available Correction dated 2020-11-12
Click to view Correction: https://doi.org/10.1038/s41746-020-00360-w
-
Authors
North, Mal https://orcid.org/0000-0001-9064-3138
Bourne, Simon https://orcid.org/0000-0002-6753-6948
Green, Ben
Chauhan, Anoop J. https://orcid.org/0000-0003-4044-6114
Brown, Tom
Winter, Jonathan https://orcid.org/0000-0002-7304-291X
Jones, Tom https://orcid.org/0000-0002-6324-7540
Neville, Dan
Blythin, Alison https://orcid.org/0000-0001-6080-0120
Watson, Alastair https://orcid.org/0000-0002-6735-2567
Johnson, Matthew https://orcid.org/0000-0001-5597-6615
Culliford, David https://orcid.org/0000-0003-1663-0253
Elkes, Jack https://orcid.org/0000-0002-4060-2394
Cornelius, Victoria
Wilkinson, Tom M. A. https://orcid.org/0000-0003-1771-3851
-
Funding
Funding for this research was provided by:
Innovate UK (SBRI Grant from Innovate UK, SBRI Grant from Innovate UK)
- License Information
-
More Information
Article History
Received: 8 November 2019
Accepted: 17 September 2020
First Online: 30 October 2020
Change Date: 12 November 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41746-020-00360-w
Competing interests
: T.W. is the co-founder, shareholder and director, S.B. is the co-founder, shareholder and director M.N. and A.B are employees of Mymhealth Limited. T.W., S.B. and M.N. have received personal fees during the conduct of the study. B.G. and T.B. received grants from Mymhealth Limited. Outside the submitted work, T.B. has received grants from GSK and personal fees from AstraZeneca, GSK, Teva, Napp Pharmaceuticals and Novartis as well as non-financial support from GSK, Teva and Novartis. Outside the submitted work, T.W. has received grants from GSK, AstraZeneca and Synairgen and has received personal fees from AstraZeneca, Synairgen and BI. A.J.C., J.W., T.J., D.N., A.W., D.C., M.J., J.E. and V.C. have nothing to disclose.
